NASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $38.99 -0.78 (-1.96%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Roivant Sciences Stock (NASDAQ:ROIV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$38.72▼$39.9050-Day Range$32.87▼$41.8152-Week Range$14.50▼$42.50Volume5.62 million shsAverage Volume10.16 million shsMarket Capitalization$28.16 billionP/E RatioN/ADividend YieldN/APrice Target$45.64Consensus RatingModerate Buy Company Overview Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions. Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support. Its portfolio has included treatments and investigational medicines for inflammatory and immune-mediated diseases, as well as other specialty indications. Founded in 2014, Roivant has built partnerships with pharmaceutical companies and research organizations to develop and commercialize products in the United States and international markets. The company is led by Chief Executive Officer Matt Gline and maintains a global biopharmaceutical and drug-development presence.AI Generated. May Contain Errors. Read More Roivant Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreROIV MarketRank™: Roivant Sciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 327th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRoivant Sciences has a consensus price target of $45.64, representing about 17.0% upside from its current price of $38.99.Amount of Analyst CoverageRoivant Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -73.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -73.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.09% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roivant Sciences has recently increased by 9.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentRoivant Sciences has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Roivant Sciences this week, compared to 6 articles on an average week.Search Interest8 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107,457,494.00 in company stock.Percentage Held by Insiders8.80% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Stock News HeadlinesWhat Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?September 18, 2026 | finance.yahoo.comRoivant Shareholders Approve Directors and Governance MattersSeptember 18, 2026 | tipranks.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 SharesSeptember 18, 2026 | insidertrades.comStifel initiates coverage of Roivant Sciences with buy ratingSeptember 17, 2026 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 17, 2026 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares of StockSeptember 2, 2026 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) Insider Sells $653,458.70 in StockAugust 22, 2026 | insidertrades.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $21.70 at the beginning of 2026. Since then, ROIV shares have increased by 79.7% and is now trading at $38.99. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative trailing twelve-month return on equity of 22.94%. Read the conference call transcript. Who are Roivant Sciences' major shareholders? Roivant Sciences' top institutional investors include Assenagon Asset Management S.A. (1.16%), Wellington Management Group LLP (0.37%), California State Teachers Retirement System (0.07%) and Squarepoint Ops LLC (0.07%). Insiders that own company stock include Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Frank Torti, Daniel Allen Gold, Eric Venker, Keith S Manchester, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roivant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/07/2026Today9/22/2026Bank of America Global Healthcare Conference9/22/2026Next Earnings (Estimated)11/09/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ROIV's financial health is in the Green zone, according to TradeSmith. ROIV has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ROIV CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees721Year Founded2014Price Target and Rating Average Price Target for Roivant Sciences$45.64 High Price Target$55.00 Low Price Target$33.00 Potential Upside/Downside+17.0%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.77 million Net Margins-3,534.96% Pretax Margin-3,848.65% Return on Equity-22.94% Return on Assets-21.53% Debt Debt-to-Equity RatioN/A Current Ratio16.72 Quick Ratio16.72 Sales & Book Value Annual Sales$8.26 million Price / Sales3,409.60 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book5.30Miscellaneous Outstanding Shares722,320,000Free Float658,759,000Market Cap$28.16 billion OptionableOptionable Beta1.12 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ROIV) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
